

Content available at: <https://www.ipinnovative.com/open-access-journals>

Indian Journal of Clinical Anaesthesia

Journal homepage: [www.ijca.in](http://www.ijca.in)

## Short Communication

## The role of vasodilators in managing chronic obstructive pulmonary disease (COPD) in ICU

Ruchi Goyal <sup>1\*</sup>, Lalit Gupta <sup>1</sup>, Sherry Marak <sup>1</sup><sup>1</sup>Dept. of Anaesthesia and Critical Care, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India

## ARTICLE INFO

## Article history:

Received 08-11-2023

Accepted 17-11-2023

Available online 28-11-2023

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

Dear Editor,

I am writing to express my experience on an important medical topic that affects millions of individuals worldwide—Chronic Obstructive Pulmonary Disease (COPD). COPD is a debilitating lung condition that compromises the lives of those who suffer from it. COPD, primarily characterized by chronic bronchitis and emphysema, is a progressive lung disease known for its debilitating symptoms, including shortness of breath, coughing, and fatigue. Despite advances in COPD management, finding effective treatments remains a challenge. In this context, vasodilators have emerged as potential game-changers in recent years in COPD management especially patients admitted in ICU.

Vasodilators are medications that dilate the blood vessels, thereby reducing resistance to blood flow and lowering blood pressure. While they are commonly used to treat cardiovascular conditions, their potential application in COPD management has been a subject of increasing interest. Vasodilators, including phosphodiesterase-5 (PDE-5) inhibitors and inhaled nitric oxide, have shown promise in improving pulmonary circulation and oxygenation in COPD patients. One of the key benefits of vasodilators in COPD management is their ability to reduce pulmonary

hypertension—a condition commonly associated with advanced stages of COPD. Elevated pulmonary pressure places additional strain on the heart, making it more difficult for patients to breathe. Vasodilators, such as sildenafil and tadalafil (PDE-5 inhibitors), have been shown to lower pulmonary artery pressure, ultimately leading to improved right ventricular function and better oxygenation.<sup>1</sup>

In the realm of COPD treatment, there has been recent exploration into the use of inhaled nitric oxide (iNO) as a vasodilator.<sup>2</sup> The mechanism of action involves iNO's ability to influence the smooth muscle cells that line the blood vessels in the lungs.<sup>3</sup> By promoting vasodilation, iNO facilitates the expansion of these vessels, enhancing blood flow and, consequently, improving oxygen exchange within the pulmonary capillaries.<sup>4</sup> This is of particular significance in the context of COPD, where impaired airflow and obstructed air passages often contribute to inadequate oxygenation. Moreover, the targeted nature of iNO's action on the pulmonary vasculature distinguishes it as a focused intervention, minimizing systemic effects. This specificity contributes to its potential as a well-tolerated and effective therapeutic option for COPD patients struggling with impaired oxygen transfer. In a study conducted by K. Ashutosh et al., a substantial decrease in pulmonary vascular resistance was observed following the administration of inhaled nitric oxide (NO), without any significant adverse events.<sup>5</sup>

\* Corresponding author.

E-mail address: [ruchigoyal403@gmail.com](mailto:ruchigoyal403@gmail.com) (R. Goyal).

Studies have demonstrated that PDE-5 inhibitors can effectively improve exercise capacity and reduce dyspnoea in COPD patients.<sup>6</sup> This is a significant development because improved exercise capacity can translate to enhanced quality of life and a reduced risk of exacerbations. The mechanism behind these positive effects involves the vasodilatory properties of PDE-5 inhibitors. By dilating blood vessels, these medications facilitate improved blood flow, potentially aiding in the delivery of oxygen to tissues and alleviating the symptoms associated with COPD.<sup>1,6</sup> It's important to note that while these findings are promising, the use of PDE-5 inhibitors in COPD management may require careful consideration of individual patient characteristics, potential side effects, and overall treatment strategies.

In addition to their impact on pulmonary hypertension, vasodilators may also offer anti-inflammatory and bronchodilator effects.<sup>7</sup> These properties can help to alleviate airway inflammation and smooth muscle constriction, both of which contribute to the symptoms experienced by COPD patients. While more research is needed to fully understand the mechanisms of these effects, the potential to target multiple aspects of COPD pathophysiology makes vasodilators a promising avenue of treatment.<sup>8</sup>

However, it's important to acknowledge that the use of vasodilators in COPD is not without challenges. First, more extensive clinical trials are needed to establish the optimal dosage, duration, and long-term safety of these medications in COPD patients. Additionally, it is crucial to identify which subgroup of COPD patients stands to benefit the most from vasodilator therapy. The variability in COPD phenotypes and the presence of comorbidities can complicate treatment decisions. Furthermore, the cost of vasodilator medications can be a concern, particularly when it comes to long-term therapy. The accessibility and affordability of these treatments for all COPD patients should be a priority in healthcare policy and practice.

In conclusion, the use of vasodilators in the management of COPD holds promise as a means to improve pulmonary circulation, alleviate symptoms, and enhance the overall quality of life for patients. The research in this field is evolving, and while challenges remain, there is a growing body of evidence suggesting that vasodilators can be a valuable addition to the COPD treatment toolkit. It is

imperative for the medical community, policymakers, and pharmaceutical companies to invest in further research and development in this area. This will help to refine the use of vasodilators in COPD, making them more effective and accessible to those who need them. The potential benefits for COPD patients are substantial, and their well-being should remain a top priority in the pursuit of advanced treatment options.

## References

1. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2017;9(9):CD002309. doi:10.1002/14651858.CD002309.
2. Hajian B, Backer JD, Vos W, Holsbeke CV, Ferreira F, Quinn DA, et al. Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension. *Int J Chron Obstruct Pulmon Dis*. 2016;11:1533–41.
3. Signori D, Magliocca A, Hayashida K, Graw JA, Malhotra R, Bellani G, et al. Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases. *Intensive Care Med Exp*. 2022;10(1):28.
4. Asadi AK, Sá RC, Kim NH, Theilmann RJ, Hopkins SR, Buxton RB, et al. Inhaled nitric oxide alters the distribution of blood flow in the healthy human lung, suggesting active hypoxic pulmonary vasoconstriction in normoxia. *J Appl Physiol (1985)*. 2015;118(3):331–43.
5. Ashutosh K, Phadke K, Jackson JF, Steele D. Use of nitric oxide inhalation in chronic obstructive pulmonary disease. *Thorax*. 2000;55(2):109–13.
6. Isa N, Mudhafar D, Ju C, Man KKC, Lau WCY, Cheng LY, et al. Effects of phosphodiesterase-5 inhibitors in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. *COPD*. 2022;19(1):300–8.
7. Liu K, Wang H, Yu SJ, Tu GW, Luo Z. Inhaled pulmonary vasodilators: a narrative review. *Ann Transl Med*. 2021;9(7):597.
8. Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. *Eur Respir J*. 2003;21(5):892–905.

## Author biography

**Ruchi Goyal**, PG Student  <https://orcid.org/0000-0003-3515-239X>

**Lalit Gupta**, Professor  <https://orcid.org/0000-0001-7291-5961>

**Sherry Marak**, PG Student  <https://orcid.org/0009-0007-2672-2078>

**Cite this article:** Goyal R, Gupta L, Marak S. The role of vasodilators in managing chronic obstructive pulmonary disease (COPD) in ICU. *Indian J Clin Anaesth* 2023;10(4):407-408.